Published in Vaccine Weekly, September 28th, 2005
This is Intercell's first commercialization agreement for the delivery of its lead vaccine product, which is planned to enter Phase 3 clinical trials in September 2005.
Intercell is planning to market the product independently from this agreement with CSL Ltd. in the United States and Europe targeting the travelers and armed forces market and replacing current suboptimal vaccines produced on mouse brain.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly